Fractures in patients with chronic kidney disease

  • S. L. Dudar Shupyk National Healthcare University of Ukraine, Department Orthopedics and Traumatology 2
Keywords: fractures, chronic kidney disease, mineral and bone disorders (CKD-MBD), treatment, prevention.

Abstract

Abstract. Despite rapid progress in improving dialysis technology in recent years, the mortality of patients treated with renal replacement therapy remains quite high. Mineral and bone disease is omnipresent in patients with chronic kidney disease (CKD) and leads to a diverse range of clinical manifestations, including bone pain and fractures. Mineral bone disorders (MBD), as well as changes in bone structure, develop at the beginning of CKD. Osteoporosis can progress according to declining of the glomerular filtration rate and contribute to the deterioration of bone strength resulted in a high risk of fracture. In CKD patients, the most common are hip fractures, femur, humerus, compression fractures of the vertebrae and pelvic fractures. CKD-MBD is characterized by disorders of calcium, phosphate, parathyroid hormone and/or vitamin D metabolism, as well as, bone regeneration, mineralization, volume, linear growth and strength violation, calcification of blood vessels, or other soft tissues. Medications that correct systemic mineral metabolism can improve bone histology in patients with CKD. However, clinical and biochemical targets used in clinical practice remain controversial, resulting in an undermanagement of bone fragility.  The clarifying of the appropriateness of medicines that act directly on the bone or affect the mineral and hormonal metabolism could be a promising strategy to prevent pathological fractures due to fragility among CKD patients.

Downloads

Download data is not yet available.

References

NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis, and therapy. osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785–795. doi: 10.1001/jama.285.6.785

Kazama JJ. Chronic kidney disease and fragility fracture. Clin Exp Nephrol. 2017;21(Suppl 1):46-52. doi:10.1007/s10157-016-1368-3.

Pimentel A, Ureña-Torres P, Zillikens MC, Bover J, Cohen-Solal M. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. Kidney Int. 2017;92(6):1343-1355. doi: 10.1016/j.kint.2017.07.021.

Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36. doi: 10.1016/j.kint.2017.04.006.

Fujiwara S, Kasagi F, Masunari N, et al. Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res. 2003;18:1547–1553. doi: 10.1359/jbmr.2003.18.8.1547. 

Torres PU, Bover J, Mazzaferro S, de Vernejoul MC, Cohen-Solal M. When, how, and why a bone biopsy should be performed in patients with chronic kidney disease. Semin Nephrol. 2014;34(6):612-25. doi: 10.1016/j.semnephrol.2014.09.004.

Schnitzler CM. Bone quality: a determinant for certain risk factors for bone fragility. Calcif Tissue Int. 1993;53(Suppl 1):S27–S31. doi: 10.1007/BF01673398. 

Yamashita J, Li X, Furman BR, et al. Collagen and bone viscoelasticity: a dynamic mechanical analysis. J Biomed Mater Res. 2002;63:31–36. doi: 10.1002/jbm.10086. 

Kazama JJ, Iwasaki Y, Fukagawa M. Uremic osteoporosis. Kidney Int Suppl (2011). 2013;3(5):446-450. doi:10.1038/kisup.2013.93. 

Maravic M, Ostertag A, Torres PU, Cohen-Solal M. Incidence and risk factors for hip fractures in dialysis patients. Osteoporos Int. 2014;25:159–165. doi: 10.1007/s00198-013-2435-1. 

Wakasugi M, Kazama JJ, Taniguchi M, et al. Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Miner Metab. 2013;31:315–321. doi: 10.1007/s00774-012-0411-z. 

Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006;17(11):3223-32. doi: 10.1681/ASN.2005111194.

Kim SM, Long J, Montez-Rath M, et al. Hip fracture in patients with non-dialysis-requiring chronic kidney disease. J Bone Miner Res. 2016;31:1803–1809. doi: 10.1002/jbmr.2862. 

Elliott MJ, James MT, Quinn RR, et al. Estimated GFR and fracture risk: a population-based study. Clin J Am Soc Nephrol. 2013;8:1367–1376. doi: 10.2215/CJN.09130912.

Fusaro M, Tripepi G, Noale M, Vajente N, Plebani M, Zaninotto M, et al. High prevalence of vertebral fractures assessed by quantitative morphometry in hemodialysis patients, strongly associated with vascular calcifications. Calcif Tissue Int. 2013;93(1):39-47. doi: 10.1007/s00223-013-9722-x.

Desmet C, Beguin C, Swine C, Jadoul M; Université Catholique de Louvain Collaborative Group. Falls in hemodialysis patients: prospective study of incidence, risk factors, and complications. Am J Kidney Dis. 2005;45(1):148-53. doi: 10.1053/j.ajkd.2004.09.027.

Stenvinkel P, Carrero JJ, von Walden F, Ikizler TA, Nader GA. Muscle wasting in end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategies. Nephrol Dial Transplant. 2016;31(7):1070-7. doi: 10.1093/ndt/gfv122.

Naylor KL, McArthur E, Leslie WD, Fraser LA, Jamal SA, Cadarette SM, et al. The three-year incidence of fracture in chronic kidney disease. Kidney Int. 2014;86(4):810-8. doi: 10.1038/ki.2013.547.

Delgado C, Shieh S, Grimes B, Chertow GM, Dalrymple LS, Kaysen GA, et al. Association of Self-Reported Frailty with Falls and Fractures among Patients New to Dialysis. Am J Nephrol. 2015;42(2):134-40. doi: 10.1159/000439000.

Maravic M, Ostertag A, Urena P, Cohen-Solal M. Dementia is a major risk factor for hip fractures in patients with chronic kidney disease. Osteoporos Int. 2016;27:1665–1669. doi: 10.1007/s00198-015-3429-y.

Shifris IM, Dudar IO. Comorbidity and survival of patients with chronic kidney disease of 5D stage. Ukrainian journal of nephrology and dialysis 2015;4(48): 30-39. doi: 10.31450/ukrjnd.4(48).2015.06.

Shifris I, Dudar I, Driyanska V, Honchar Y, Savchenko V. Comorbidity status and interleukin-10 levels in end-stage renal disease patients treated with hemodialysis. Pol Merkur Lekarski. 2021;49(291):182-186.

Lin JC, Liang WM. Mortality and complications after hip fracture among elderly patients undergoing hemodialysis. BMC Nephrol. 2015;16:100. doi: 10.1186/s12882-015-0099-0. 

Nickolas TL, Stein EM, Dworakowski E, Nishiyama KK, Komandah-Kosseh M, Zhang CA, et al. Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res. 2013;28(8):1811-20. doi: 10.1002/jbmr.1916.

Maruyama Y, Taniguchi M, Kazama JJ, Yokoyama K, Hosoya T, Yokoo T, et al. A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan. Nephrol Dial Transplant. 2014;29(8):1532-8. doi: 10.1093/ndt/gfu055.

Negri AL, Del Valle EE, Zanchetta MB, Nobaru M, Silveira F, Puddu M, et al. Evaluation of bone microarchitecture by high-resolution peripheral quantitative computed tomography (HR-pQCT) in hemodialysis patients. Osteoporos Int. 2012;23(10):2543-50. doi: 10.1007/s00198-011-1890-9.

Trombetti A, Stoermann C, Chevalley T, B Van Rietbergen, F R Herrmann, P-Y Martin, et al. Alterations of bone microstructure and strength in end-stage renal failure. Osteoporos Int. 2013;24:1721–1732. doi: 10.1007/s00198-012-2133-4.

Kazama JJ, Matsuo K, Iwasaki Y, Fukagawa M. Chronic kidney disease and bone metabolism. J Bone Miner Metab. 2015;33:245–252. doi: 10.1007/s00774-014-0639-x. 

Iwasaki Y, Yamato H, Nii-Kono T, A Fujieda, M Uchida, A Hosokawa, et al. Insufficiency of PTH action on bone in uremia. Kidney Int Suppl. 2006;102:S34–S36. doi: 10.1038/sj.ki.5001600.

Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl. 1992;38:S62–S67.

Seref-Ferlengez Z, Kennedy OD, Schaffler MB. Bone microdamage, remodeling and bone fragility: how much damage is too much damage? Bonekey Rep. 2015;4:644. doi: 10.1038/bonekey.2015.11. 

Kazama JJ. Bone histology in chronic kidney disease-related mineral and bone disorder. Ther Apher Dial. 2011;15(Suppl 1):23–25. doi: 10.1111/j.1744-9987.2011.00923.x. 

Komaba H, Shiizaki K, Fukagawa M. Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges. Expert Opin Biol Ther. 2010;10:1729–1742. doi: 10.1517/14712598.2010.518614.

Ott SM. Bisphosphonate safety and efficacy in chronic kidney disease. Kidney Int. 2012;82:833–835. doi: 10.1038/ki.2012.253.

Güerri-Fernández RC, Nogués X, Quesada Gómez JM, Torres Del Pliego E, Puig L, García-Giralt N, et al. Microindentation for in vivo measurement of bone tissue material properties in atypical femoral fracture patients and controls. J Bone Miner Res. 2013;28(1):162-8. doi: 10.1002/jbmr.1731.

Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1-23. doi: 10.1002/jbmr.1998.

Mahjoub Z, Jean S, Leclerc JT, Brown JP, Boulet D, Pelet S, et al. Incidence and characteristics of atypical femoral fractures: clinical and geometrical data. J Bone Miner Res. 2016;31:767–776. doi: 10.1002/jbmr.2748.

Okada N, Kawazoe K, Teraoka K, Kujime T, Abe M, Shinohara Y, et al. Identification of the risk factors associated with hypocalcemia induced by denosumab. Biol Pharm Bull. 2013;36:1622–1626. doi: 10.1248/bpb.b13-00496.

Chen CL, Chen NC, Hsu CY, Chou KJ, Lee PT, Fang HC, et al. An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis. J Clin Endocrinol Metab. 2014;99:2426–2432. doi: 10.1210/jc.2014-1154.

Saito O, Saito T, Asakura S, Akimoto T, Inoue M, Ando Y, et al. Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes. Int J Endocrinol Metab. 2012;10(2):464-9. doi: 10.5812/ijem.3794.

Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, et al; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. J Am Soc Nephrol. 2015 Jun;26(6):1466-75. doi: 10.1681/ASN.2014040414.

Fusaro M, Giannini S, Gallieni M, Noale M, Tripepi G, Rossini M, et al. Calcimimetic and vitamin D analog use in hemodialyzed patients is associated with increased levels of vitamin K dependent proteins. Endocrine. 2016;51:333–341. doi: 10.1007/s12020-015-0673-z.

Hocher B, Armbruster FP, Stoeva S, Reichetzeder C, Grön HJ, Lieker I, et al. Measuring parathyroid hormone (PTH) in patients with oxidative stress—do we need a fourth generation parathyroid hormone assay? PLoS One. 2012;7:e40242. doi: 10.1371/journal.pone.0040242.

Yamamoto S, Kido R, Onishi Y, Fukuma S, Akizawa T, Fukagawa M, et al. Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients. PLoS One. 2015;10:e0122691. doi: 10.1371/journal.pone.0122691.

Kato A, Kido R, Onishi Y, Kurita N, Fukagawa M, Akizawa T, et al. Association of serum bicarbonate with bone fractures in hemodialysis patients: the mineral and bone disorder outcomes study for Japanese CKD stage 5D patients (MBD-5D). Nephron Clin Pract. 2014;128:79–87. doi: 10.1159/000365089.


Abstract views: 200
PDF Downloads: 18496
Published
2021-08-10
How to Cite
Dudar, S. L. (2021). Fractures in patients with chronic kidney disease. Ukrainian Journal of Nephrology and Dialysis, (3(71), 88-96. https://doi.org/10.31450/ukrjnd.3(71).2021.10